Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study.

doi:10.1158/1078-0432.CCR-19-3897

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2020

Casadei-Gardini Andrea, Marisi Giorgia, Dadduzio Vincenzo, Gramantieri Laura, Faloppi Luca, Ulivi Paola, Foschi Francesco Giuseppe, Tamburini Emiliano, Vivaldi Caterina, Rizzato Mario Domenico, Ielasi Luca, Canale Matteo, Conti Fabio, Rudnas Britt, Fornaro Lorenzo, Silvestris Nicola, Silletta Marianna, Cardellino Giovanni Gerardo, Lonardi Sara, Fornari Francesca, Orsi Giulia, Rovesti Giulia, Zagonel Vittorina, Cascinu Stefano, Scartozzi Mario

Abstract excerpt

PURPOSE: After 10 years of clinical practice and research studies, there are still no validated prognostic or predictive factors of response to sorafenib for hepatocellular carcinoma (HCC). On the basis of the results of our two retrospective studies, we designed the multicenter INNOVATE study with the aim to validate the role of nitric oxide synthase 3 (NOS3) and ANGPT2 polymorphisms in patients with HCC treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiopoietin-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Hepatocellular

Share to Drug Resistance, Neoplasm

Share to Liver Neoplasms

Share to Neoplasm Staging

Share to Nitric Oxide Synthase Type III

Share to Progression-Free Survival

Share to Sorafenib

Source

Open in PubMed

Identifiers

PMID: 32371540
DOI: 10.1158/1078-0432.CCR-19-3897

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study.PMID 32371540Read ↗

Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.Semantic proximity Read ↗

Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib.Semantic proximity Read ↗

Genetic biomarkers of sorafenib response in patients with hepatocellular carcinomaSemantic proximity Read ↗

Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study.Semantic proximity Read ↗

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.Semantic proximity Read ↗

Abnormal Expression of NOS3 and Association with Clinical Outcome are Highly Cancer Dependent as Revealed through Pan-Cancer AnalysisSemantic proximity Read ↗

A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma.Semantic proximity Read ↗

Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib.Semantic proximity Read ↗

VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.Semantic proximity Read ↗

GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial.Semantic proximity Read ↗

Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).Semantic proximity Read ↗

Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.